Form 4: Ideaya Biosciences SVP, General Counsel Douglas B. Snyder Reports Stock Option Grant
SEC Form 4
Douglas B. Snyder, SVP, General Counsel of Ideaya Biosciences, reports the acquisition of stock options for 33,000 shares of common stock on February 27, 2025.
Summary
- On February 27, 2025, Douglas B. Snyder, SVP, General Counsel of Ideaya Biosciences, reported acquiring stock options for 33,000 shares of common stock at an exercise price of $20.24.
- These options vest over four years, starting January 1, 2025, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a routine disclosure of stock option grants to an executive.
Positives
- The grant of stock options to a key executive aligns their interests with those of the shareholders.
Future Outlook
NA
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and retain key personnel.
Stakeholder Impact
- The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 01/01/2025 | Vesting Commencement Date |
| 02/27/2025 | Transaction Date: Stock option grant to Douglas B. Snyder |
| 02/28/2025 | Date of Form 4 signature |
| 02/26/2035 | Expiration Date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.